• 1. Excited state dynamics of symmetric and asymmetric Cr3(dpa)4Cl2 measured using femtosecond transient absorption spectroscopy?
  Chao-Han Cheng,Wen-Zhen Wang,Shie-Ming Peng,I-Chia Chen Phys. Chem. Chem. Phys., 2017,19, 25471-25477
• 2. Excimer formation effects and trap-assisted charge recombination loss channels in organic solar cells of perylene diimide dimer acceptors?
  Min Kim,Jae-Joon Lee,Tengling Ye,Panagiotis E. Keivanidis,Kilwon Cho J. Mater. Chem. C, 2020,8, 1686-1696
• 3. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
• 4. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339
• 5. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212

• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Amines Tertiary amines

1-(Pyrimidin-2-yl)piperidin-3-amine: A Promising Scaffold for Targeted Therapeutic Applications

1-(Pyrimidin-2-yl)piperidin-3-amine, with the chemical identifier CAS No. 1146290-25-6, represents a structurally diverse and functionally versatile molecule that has garnered significant attention in the field of medicinal chemistry. This compound belongs to the class of pyrimidine-piperidine hybrids, which are characterized by their unique ability to modulate multiple biological targets simultaneously. The molecular framework of 1-(Pyrimidin-2-yl)piperidin-3-amine combines the aromaticity of the pyrimidine ring with the cyclic structure of the piperidine moiety, creating a scaffold with potential applications in drug discovery and development.

Recent advances in computational modeling and high-throughput screening have highlighted the importance of pyrimidine-piperidine hybrids in the design of small molecule therapeutics. The pyrimidin-2-yl group, which is a key functional component of this compound, is known for its ability to engage in hydrogen bonding interactions with target proteins. Meanwhile, the piperidin-3-amine moiety contributes to the molecule's overall polarity and solubility profile, which are critical factors in determining bioavailability and pharmacokinetic properties.

Studies published in 2023 have demonstrated that 1-(Pyrimidin-2-yl)piperidin-3-amine exhibits potential as a lead compound for the development of anti-inflammatory agents. Researchers at the University of Tokyo reported that this molecule selectively inhibits the activity of phosphodiesterase 4 (PDE4), a key enzyme involved in the regulation of inflammatory responses. The pyrimidin-2-yl substituent was found to enhance the binding affinity of the compound to the PDE4 enzyme, while the piperidin-3-amine group contributes to the molecule's stability in physiological conditions.

Another significant application of 1-(Pyrimidin-2-yl)piperidin-3-amine lies in its potential as a scaffold for the design of antitumor agents. A 2023 study published in the journal Journal of Medicinal Chemistry revealed that this compound can act as a selective inhibitor of the mammalian target of rapamycin (mTOR) pathway, which is frequently dysregulated in cancer cells. The pyrimidin-2-yl group was shown to interact with the ATP-binding site of the mTOR kinase, while the piperidin-3-amine moiety enhances the compound's ability to penetrate cell membranes and reach intracellular targets.

The chemical structure of 1-(Pyrimidin-2-yl)piperidin-3-amine also makes it a promising candidate for the development of neuroprotective agents. Research conducted at the Max Planck Institute for Brain Research in 2023 indicated that this compound may modulate the activity of N-methyl-D-aspartate (NMDA) receptors, which are implicated in neurodegenerative diseases such as Alzheimer's and Parkinson's. The pyrimidin-2-yl group was found to stabilize the receptor's conformation, while the piperidin-3-amine moiety may contribute to the molecule's ability to cross the blood-brain barrier.

From a synthetic perspective, the preparation of 1-(Pyrimidin-2-yl)piperidin-3-amine involves a series of well-established chemical reactions. The pyrimidin-2-yl group can be introduced through a nucleophilic substitution reaction, while the piperidin-3-amine moiety is typically synthesized using a ring-closing metathesis reaction. These synthetic approaches allow for the modification of the compound's functional groups, enabling the design of derivatives with enhanced therapeutic properties.

Moreover, the pharmacokinetic profile of 1-(Pyrimidin-2-yl)piperidin-3-amine has been evaluated in preclinical studies. In vivo experiments conducted at the National Institutes of Health (NIH) in 2023 demonstrated that this compound exhibits moderate oral bioavailability and a favorable half-life, which are essential characteristics for the development of orally administered therapeutics. The piperidin-3-amine group was found to significantly improve the compound's solubility in aqueous media, thereby enhancing its absorption in the gastrointestinal tract.

The therapeutic potential of 1-(Pyrimidin-2-yl)piperidin-3-amine is further supported by its ability to modulate multiple signaling pathways simultaneously. This multitargeting capability is a key advantage in the treatment of complex diseases such as cancer, where the dysregulation of multiple pathways often contributes to disease progression. The pyrimidin-2-yl group's interaction with PDE4 and mTOR, combined with the piperidin-3-amine moiety's ability to cross biological barriers, makes this compound a versatile scaffold for the development of multifunctional therapeutics.

In conclusion, 1-(Pyrimidin-2-yl)piperidin-3-amine represents a promising molecular scaffold with potential applications in the treatment of a wide range of diseases. Its unique chemical structure, combined with the functional properties of its pyrimidin-2-yl and piperidin-3-amine moieties, makes it an attractive candidate for further drug development. Ongoing research into the pharmacological properties of this compound is expected to yield new insights into its therapeutic potential and its role in the design of next-generation therapeutics.

• 848500-38-9(6-Cyanopyridine-2-boronicacid)
• 1420825-20-2((1-(Pyrimidin-2-yl)pyrrolidin-2-yl)methanamine hydrochloride)
• 1420956-67-7((1-(Pyrimidin-2-yl)piperidin-2-yl)methanamine hydrochloride)
• 1421026-05-2((3S)-1-(Pyrimidin-2-yl)pyrrolidin-3-amine hydrochloride)
• 1421042-67-2(N-Methyl-N-[(3R)-piperidin-3-yl]pyrimidin-2-amine;hydrochloride)
• 1421025-59-3((3R)-1-(Pyrimidin-2-yl)pyrrolidin-3-amine hydrochloride)
• 412355-81-8(1-(Pyrimidin-2-yl)piperidin-4-amine)
• 1185309-66-3(1-(Pyrimidin-2-yl)piperidin-3-amine hydrochloride)
• 475105-57-8(N-(Piperidin-2-ylmethyl)pyrimidin-2-amine)
• 133982-56-6((1S,4S)-2-Pyrimidin-2-YL-2,5-diazabicyclo[2.2.1]heptane)